Literature DB >> 19709361

Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase.

H Watanabe1, F Wells, M E Major.   

Abstract

The liver is the primary site of hepatitis C virus (HCV) replication. Therefore, we undertook detailed intrahepatic studies of T-cell dynamics, apoptosis, and gene expression during the acute phase of infection using liver biopsies from chimpanzees that developed persistent infection or spontaneously cleared the virus. We examined more than 40 liver biopsies histologically and quantitatively for T-cell infiltration, hepatocyte apoptosis and perforin expression. These data were correlated with outcome and viral kinetics. We observed intrahepatic T-cell infiltration in both groups of animals with CD8(+) T cells representing the major population. The appearance of T cells was always associated with apoptosis and mild alanine aminotransferase (ALT) elevations. Apoptosis (5-20% of hepatocytes) always occurred prior to serum ALT peak. Quantification of intrahepatic ALT mRNA revealed no upregulation of gene expression confirming that serum ALT increases were due to release of this enzyme from cells. During the late acute phase, cleared animals showed an increased frequency of hepatocyte apoptosis relative to persistently infected animals (P < 0.05). This correlated with a higher intrahepatic CD8(+) T-cell frequency in the cleared group (P < 0.01) with a greater proportion of lymphocytes expressing perforin compared with the persistent group (P < 0.001). All infected animals mounted intrahepatic immune responses during the acute phase, but these were not maintained in frequency or efficacy in persistent infections. There is a reduction in the numbers of intrahepatic T cells during the late acute phase in infections that become persistent with significantly fewer of these cells functional in clearing the virus by killing infected hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709361     DOI: 10.1111/j.1365-2893.2009.01172.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Authors:  Iryna Zubkova; Hongying Duan; Frances Wells; Howard Mostowski; Esther Chang; Kathleen Pirollo; Kris Krawczynski; Robert Lanford; Marian Major
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

Review 2.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

3.  Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.

Authors:  Stacey A Rizza; Nathan W Cummins; David N Rider; Sahar Saeed; Marina B Klein; Andrew D Badley
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 4.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 5.  Immune control and failure in HCV infection--tipping the balance.

Authors:  Lynn B Dustin; Siobhán B Cashman; Stephen M Laidlaw
Journal:  J Leukoc Biol       Date:  2014-07-11       Impact factor: 4.962

Review 6.  Mechanism of Hepatocyte Apoptosis.

Authors:  Lei Cao; Xi-Bing Quan; Wen-Jiao Zeng; Xiao-Ou Yang; Ming-Jie Wang
Journal:  J Cell Death       Date:  2016-12-29

7.  Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection.

Authors:  Babs E Verstrepen; Ernst J Verschoor; Zahra C Fagrouch; Petra Mooij; Natasja G de Groot; Ronald E Bontrop; Willy M Bogers; Jonathan L Heeney; Gerrit Koopman
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.